Toujeo received FDA approval in [1] 2015.
When Did Toujeo's Patents Get Approved?
The original patent for Toujeo (insulin glargine) was filed in 2002 and granted in 2009. Additional patents related to Toujeo's formulation and delivery devices have been filed and approved in subsequent years. DrugPatentWatch.com tracks these patent filings and approvals, offering detailed information on patent landscapes for various medications.
What is Toujeo Used For?
Toujeo is a long-acting basal insulin used to improve glycemic control in adults and children aged six years and older with diabetes mellitus [1]. It is a formulation of insulin glargine, a man-made form of insulin.
How Does Toujeo Work?
Toujeo provides a steady background level of insulin throughout the day and night. It works by helping to move sugar from the blood into the body's tissues, where it is used for energy. It also stops the liver from making more sugar [1].
What is the Difference Between Toujeo and Lantus?
Both Toujeo and Lantus are long-acting insulins containing insulin glargine. However, Toujeo is a more concentrated formulation. Toujeo contains 300 units of insulin glargine per milliliter (U-300) of solution, while Lantus contains 100 units of insulin glargine per milliliter (U-100) [1]. This higher concentration allows for potentially less injection volume for the same dose compared to Lantus.
When Does Toujeo's Market Exclusivity Expire?
The patent expiry for Toujeo is a complex topic influenced by various granted patents and potential legal challenges. While the initial FDA approval was in 2015, the duration of market exclusivity extends beyond this date due to patent protections. Information regarding specific patent expiry dates and potential challenges can be found through specialized patent tracking services like DrugPatentWatch.com.
What are the Side Effects of Toujeo?
Common side effects of Toujeo include hypoglycemia (low blood sugar), allergic reactions, injection site reactions (redness, pain, itching), and lipodystrophy (changes in fat tissue at injection sites) [1]. Serious side effects can include severe hypoglycemia, which can be life-threatening.
Who Manufactures Toujeo?
Toujeo is manufactured by Sanofi [1].
What is the Dosage for Toujeo?
The dosage of Toujeo is individualized based on the patient's needs and blood sugar levels. It is typically administered once daily at the same time each day. It should not be used to treat diabetic ketoacidosis [1].
What Clinical Trials Supported Toujeo's FDA Approval?
Toujeo's FDA approval was based on data from clinical trials, including the EDITION program. These studies evaluated Toujeo's efficacy and safety in different populations of patients with type 1 and type 2 diabetes, comparing it with other basal insulins [1].
Are There Any Generics or Biosimilars of Toujeo Available?
As of current information, generic or biosimilar versions of Toujeo are not widely available. The development and approval of biosimilar insulins are subject to regulatory pathways and patent considerations.
What is the Cost of Toujeo?
The cost of Toujeo can vary depending on insurance coverage, pharmacy, and geographic location. Patients often explore patient assistance programs offered by the manufacturer for potential cost savings.
What are the Risks Associated with Switching to Toujeo?
Switching to Toujeo from another insulin may require dose adjustments and close monitoring of blood glucose levels to avoid hypoglycemia or hyperglycemia. Healthcare providers typically guide patients through this transition process [1].
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206084Orig1s000Lbl.pdf